Li R, et al. - In lung adenocarcinoma patients, irrespective of therapy, researchers examined the pure prognostic role of epidermal growth factor receptor (EGFR) mutation status and subtype via retrospectively recruiting 119 cases of completely resected pathological stage I lung adenocarcinoma subjects who got no postoperative chemotherapy or tyrosine kinase inhibitors. Results revealed that EGFR mutations were found in 54 (45.4%) subjects, including two common mutation subtypes: 32 in-frame deletion within exon 19 (19del) and 19 point mutation within exon 21 (L858R). No difference was found in survival between patients with EGFR mutations and those without. Findings also revealed that the patients harboring EGFR 19del mutation had survival advantage vs those harboring EGFR L858R mutation.